By following this link you'll go directly to the site map at the end of each page
IT (EN)
   Person in charge: Barbara Ensoli
You're in:
 Recently updated

2documents

Improving the effect of HIV drugs by the use of a vaccine

A vaccine containing a protein necessary for virus replication can boost an HIV-infected patient’s immune system, according to clinical research published in the open access journal Retrovirology. This boost can result in increased effectiveness of antiretroviral drugs.

Published 06-25-2015 in Highlights , last update 06-25-2015 More...

Share: 

1document

State of Art of Anti-HIV/AIDS Vaccine Clinical Trials - update on 1/04/2014

State of Art of Anti-HIV/AIDS Vaccine Clinical Trials based on the recombinant biologically active HIV-1 Tat protein sponsored by ISS updated on april 1st 2014.

Published 11-28-2013 in Vaccines against HIV/AIDS , last update 04-01-2014 More...

Share: 

About us

Our aim is fighting HIV/AIDS and associated syndromes by developing vaccines and new therapeutic approaches based on studies of the pathogenic mechanisms of HIV infection and progression. The NAC organization reflects the aim to put into effect a “translational” research.

Published 03-04-2013 in About us , last update 03-28-2014 More...

Share: 

1document

BARBARA ENSOLI WAS APPOINTED AMONG THE NEW MEMBERS OF THE ERC

Barbara Ensoli, Director of the National AIDS Center- ISS, was appointed among the new members of the European Research Council (European Research Council,...

Published 11-14-2012 in Highlights , last update 03-28-2014 More...

Share: 

UNRAVELING THE MECHANISMS REQUIRED FOR HIV VACCINE PROTECTION

As published today in PLoS ONE, by binding the Envelope protein present on virus particles, HIV Tat forms a new virus entry complex that favours the infection of cells present at the portals of virus entry (i.e. dendritic cells, macrophages). These cells represent also key HIV reservoirs that ensure the persistence of HIV in the host even under an "effective" antiretroviral treatment. By binding Env, Tat renders ineffective anti-Env antibodies at blocking virus entry in target cells. Thus, both anti-Tat and anti-Env antibodies are required for efficient HIV neutralization and should be both present to block HIV acquisition and spreading, but also the persistent infection and residual disease which is still present under antiretroviral therapy.

"This finding...

Published 11-14-2012 in Highlights , last update 03-28-2014 More...

Share: 

Legal information


© - Istituto Superiore di Sanità Viale Regina Elena 299 - 00161 - Roma (I)
Partita I.V.A. 03657731000 - C.F. 80211730587 - Legal information

ISS Home

Informiamo i visitatori, in virtù della individuazione delle modalità semplificate per l'informativa e l'acquisizione del consenso per l'uso dei cookie - 8 maggio 2014 (Pubblicato sulla Gazzetta Ufficiale n. 126 del 3 giugno 2014), che questo sito utilizza direttamente solo cookie tecnici.[Ho letto]